Information & sources

Sources and publication dates for the company information, research updates and documents on this site.

Current science and company information

The pipeline is based on the interim results announcement dated 25 August 2026. Later company announcements are available in the investor section.

AI-assisted drug discovery

The platform description draws on printed pages 5 and 10 of the interim report issued on 28 September 2026. This section was checked on 4 October 2026; pipeline status continues to use the August announcement identified above.

News and historical material

Older articles describe events and information as they stood on their publication dates. For current development progress, see the pipeline and latest announcements. English translations of Chinese articles are identified on the article page. Downloadable documents are available in the languages in which they were published.

Medicine information

Medicine resources are intended for healthcare professionals. Indications and approvals vary by territory; investigational uses are not approved uses.

Scientific artwork

The homepage illustrates efsubaglutide alfa: two chains, each containing a GLP-1 analogue connected through a linker to modified human IgG2 Fc. Red and cyan identify whole chains. Sequence composition follows the WHO International Nonproprietary Names record; local Fc and GLP-1 shapes use PDB 4HAF and 1D0R references. Connecting regions and the overall pose are modeled illustrations. The 28-second cycle is artistically authored, not measured molecular motion or a demonstration of drug action. Glycans and atomic side-chain detail are omitted, and some Fc residues remain unresolved; this is not an experimentally validated complete drug structure.

The Science page retains a separate human IgG2 Fc reference rendering based on PDB 4HAF. It shows the Fc fragment rather than the complete fusion protein.

The GLP-1/receptor image in the AI-assisted discovery section is rendered from atomic coordinates in public structure PDB 3IOL: receptor chain A and GLP-1 peptide chain B in biological assembly 1, with waters and crystallization detergent omitted. It shows the receptor extracellular domain, not the complete receptor, and does not represent an Innogen candidate or an AI-platform research result.PDB 3IOL ↗

Contact and feedback

This is a website recreation preview, not an official company publication. The original information check was on 15 September 2026; the later check for the AI section is identified above.